X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    The Falling Graph of Dose Contract Manufacturing

    Q3 Market Capitalization Declines For Top Biopharma Firms

    Arena Financial results

    EMA Urges The Withdrawal of Pholcodine Drugs From EU Market

    Launch of The First Pipeline Assessment By Vaccines Europe

    Pfizer and BioNTech Dose First Participants in the U.S. as Part of Global COVID-19 mRNA Vaccine Development Program

    Non-Vaccine mRNA Therapeutics To Earn $2 Billion By 2028

    Redesigning The Human Medicines Directive And Regulation

    Redesigning The Human Medicines Directive And Regulation

    AI Customizes Synthesized DNA For Medication Development

    Start of A Multi-Drug Trial For Precision Medicine Cancer

    A Single, Linked Foundation Is Transforming Digital Trials

    CSL And uniQure – $3.5M Haemophilia B Gene Cure Clears FDA

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    The Falling Graph of Dose Contract Manufacturing

    Q3 Market Capitalization Declines For Top Biopharma Firms

    Arena Financial results

    EMA Urges The Withdrawal of Pholcodine Drugs From EU Market

    Launch of The First Pipeline Assessment By Vaccines Europe

    Pfizer and BioNTech Dose First Participants in the U.S. as Part of Global COVID-19 mRNA Vaccine Development Program

    Non-Vaccine mRNA Therapeutics To Earn $2 Billion By 2028

    Redesigning The Human Medicines Directive And Regulation

    Redesigning The Human Medicines Directive And Regulation

    AI Customizes Synthesized DNA For Medication Development

    Start of A Multi-Drug Trial For Precision Medicine Cancer

    A Single, Linked Foundation Is Transforming Digital Trials

    CSL And uniQure – $3.5M Haemophilia B Gene Cure Clears FDA

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Manufacturing

Fraunhofer IZI Selects Lonza’s MODA-ES Solution to Digitalize Manufacturing Operation

Content Team by Content Team
7th December 2022
in Manufacturing, Middle East and South Asia, Press Statements
Lonza Launches Next Generation 4D-Nucleofector Cell Transfection Platform with Proven Performance and Enhanced Ease of Use
Fraunhofer IZI, one of Europe’s leading manufacturers of cell and gene therapies for clinical trials, intends to digitalize its manufacturing operations with MODA-ES®, the Manufacturing Execution System from Lonza. Fraunhofer IZI will use Lonza’s MODA-ES® to facilitate its transition from an entirely paper-based, manual documentation process to an automated, fully electronic GMP-compliant system.
 
Manufacturing cell and gene therapies — advanced therapy medicinal products — requires extensive documentation of all manufacturing and verification steps to ensure patient safety and GMP compliance. For organizations with complex workflows, selecting the right electronic batch record solution is critical.

Dr. Gerno Schmiedeknecht, Head of the Department GMP Cell and Gene Therapy, Fraunhofer IZI, commented: “With the introduction of fully electronic batch documentation, manufacturing and batch release for our customers and partners will be even safer, faster, more cost-effective and generally more efficient. In addition, this measure leads to higher flexibility in a potential pandemic situation, as the process of reviewing the batch documentation and the batch release, in particular, can largely be carried out in remote mode without direct onsite presence.”

David McErlane, SVP, Head of Bioscience, Lonza, added: “We are excited to support Fraunhofer IZI with their MODA-ES® Implementation. Electronic batch records have been unattainable to most of the industry due to cost constraints and flexibility concerns. With a deep understanding of the challenges faced by cell and gene manufacturers, we designed MODA-ES® with the end user in mind to provide a cost-effective and usable solution that meets our customers’ requirements.”

The MODA® Platform bridges the gap between manufacturing and quality control, providing a mechanism to produce a single electronic batch record. Lonza’s manufacturing and lab execution software enables data capture and provides workflow and analytical tools to expedite product release. With a focus on a user-centric, scalable solution that may be implemented in an accelerated timeline, the MODA® Platform supports customers in their efforts to realize their digitalization goals.

Previous Post

Could The New 3D Substances Enhance The Delivery of Drugs?

Related Posts

The Falling Graph of Dose Contract Manufacturing
Drug Development

Q3 Market Capitalization Declines For Top Biopharma Firms

7th December 2022
Arena Financial results
Drug Development

EMA Urges The Withdrawal of Pholcodine Drugs From EU Market

7th December 2022
Manufacturing

Pharma Exports of India Grew 138% since 2013-14

24th November 2022
Manufacturing

OSD Contract Manufacturing To Hit $54.7 Billion by 2030

14th November 2022
Manufacturing

OSD Contract Manufacturing Sector Valued At $54.7bn By 2030

10th October 2022
Press Statements

Final Report ACHEMA 2022

19th September 2022

Latest News

Lonza Launches Next Generation 4D-Nucleofector Cell Transfection Platform with Proven Performance and Enhanced Ease of Use
Manufacturing

Fraunhofer IZI Selects Lonza’s MODA-ES Solution to Digitalize Manufacturing Operation

7th December 2022
Engine Biosciences expands its digital drug discovery pipeline with $43M round
News

Could The New 3D Substances Enhance The Delivery of Drugs?

7th December 2022
The Falling Graph of Dose Contract Manufacturing
Drug Development

Q3 Market Capitalization Declines For Top Biopharma Firms

7th December 2022
Arena Financial results
Drug Development

EMA Urges The Withdrawal of Pholcodine Drugs From EU Market

7th December 2022
Drug Development

Launch of The First Pipeline Assessment By Vaccines Europe

5th December 2022
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In